Tibet AIM Pharm. Inc. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 538.3 million compared to CNY 591.77 million a year ago.

Revenue was CNY 538.3 million compared to CNY 591.77 million a year ago. Net income was CNY 23.89 million compared to CNY 21.25 million a year ago. Basic earnings per share from continuing operations was CNY 0.13 compared to CNY 0.11 a year ago.

Diluted earnings per share from continuing operations was CNY 0.13 compared to CNY 0.11 a year ago.